The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
| Autor: | Silvia Uccella, Ritsuko Seki, Diana O. Treaba, Jorge J. Castillo, Jun-Min Li, Brady E Beltran, Moo-Kon Song, Ivana Ilić, Dariusz Stachurski, Heidi Nurmi, Sirpa Leppä, James N. Butera |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_treatment Kaplan-Meier Estimate Logistic regression Antibodies Monoclonal Murine-Derived Young Adult Immunophenotyping Chemoimmunotherapy Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over Chemotherapy business.industry Hematology Middle Aged Prognosis medicine.disease Lymphoma Oncology Monoclonal Female Rituximab Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma Algorithm Algorithms medicine.drug |
| Zdroj: | Leukemia Research. 36:413-417 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2011.12.012 |
| Popis: | Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL treated with rituximab-containing regimens. In this patient-level meta-analysis, retrospective data from 712 newly diagnosed DLBCL patients treated with chemoimmunotherapy from 7 centers were analyzed. GC and non-GC profiles were defined according to the Hans algorithm. Although the non-GC profile showed a trend towards worse overall survival (HR 1.24, 95% CI 0.92-1.66; p=0.15) and progression-free survival (HR 1.29, 95% CI 0.96-1.73; p=0.09), it did not retain its value in the multivariate survival analysis. Additionally, the non-GC profile was independently associated with worse complete response rates (OR 0.55, 95% CI 0.37-0.83; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect